Maolac, an Israel-based foodtech startup, raised USD3.2M in Seed funding.
The round was led by OurCrowd with participation from The Kitchen FoodTech Hub, The Food Tech Lab, Ventures Israel, NAOMI Investments, and Mediterranean Towers Ventures.
The company intends to use the funds to build a state-of-the-art facility that will feature small-scale production capabilities. The facility will also be able to create analytics and samples for customers and clinical trials.
Founded in 2018 by biomedical engineer Maya Ashkenazi-Otmazgin, immunity expert Dr. Ariel Orbach, and Mr. Eli Lerner, Maolac provides technology that relies on a bio-convergence platform for the discovery of proteins, based on proprietary machine learning and natural language processing search algorithms.
The first Maolac product line consists of a highly potent anti-inflammatory product for humans. Initially, this will target athletes to help reduce muscle strain and improve recovery time. The product line will also target the elderly, to support active living and improved mobility. It will form the basis for the next generation of gut health solutions for humans and pets to help prevent severe cases of gut inflammation.
The company has identified more than 1,500 known bio-active proteins in human breast milk, discovered that bovine colostrum has over 400 homolog proteins with more than a 95% bio-similarity to human breast milk, which can be extracted. Maolac creates thousands of high-impact human functional milk protein mixtures, tailor-made for various immune-boosting applications.
FinSMEs
06/07/2022